尽管HIV载量持续可检测到，但CD4+细胞计数仍有所改善。 - Suppr

Suppr

超能文献

Improvement in CD4+ cell counts despite persistently detectable HIV load.

作者信息

Levitz S M

出版信息

N Engl J Med. 1998 Apr 9;338(15):1074-5. doi: 10.1056/NEJM199804093381517.

DOI:10.1056/NEJM199804093381517

PMID:9537882

Abstract

摘要

相似文献

Improvement in CD4+ cell counts despite persistently detectable HIV load.尽管HIV载量持续可检测到，但CD4+细胞计数仍有所改善。

N Engl J Med. 1998 Apr 9;338(15):1074-5. doi: 10.1056/NEJM199804093381517.

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.利托那韦和沙奎那韦与齐多夫定和拉米夫定联合使用的安全性和有效性。

Clin Pharmacol Ther. 1999 Jun;65(6):661-71. doi: 10.1016/S0009-9236(99)90088-7.

The end of AIDS?艾滋病的终结？

Newsweek. 1996 Dec 2;128(23):64-8, 71, 73.

[Antiretroviral therapy in patients infected with HIV-1].[HIV-1感染患者的抗逆转录病毒治疗]

Medicina (B Aires). 1998;58 Suppl 1:49-56.

High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.三联联合疗法中断后血浆和细胞内HIV载量的高反弹

AIDS. 1998 Dec 3;12(17):2358-9.

Indinavir--study highlights importance of CD4+ counts over viral load.

TreatmentUpdate. 1998 Nov;10(9):2-3.

Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.接受联合抗逆转录病毒治疗的患者中CD4(+) T细胞计数的估计年均变化率。

Antivir Ther. 2010;15(4):563-70. doi: 10.3851/IMP1559.

[AIDS triple therapy. The gap between viral load and side effects].[艾滋病三联疗法。病毒载量与副作用之间的差距]

Fortschr Med. 1998 Sep 30;116(27):4-5.

Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.接受利托那韦、齐多夫定和扎西他滨三联疗法治疗的初治晚期HIV-1感染患者的病毒载量降低，T淋巴细胞数量增加。

Antivir Ther. 1997 Jul;2(3):175-83.

An evaluation of drug cocktail combinations for their immunological value in preventing/remitting opportunistic infections.

Posit Health News. 1998 Spring(No 16):2-4.

引用本文的文献

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.HIV 蛋白酶抑制剂奈非那韦和洛匹那韦/利托那韦可显著改善感染 SARS-CoV-2 的叙利亚仓鼠的肺部病理，尽管它们没有抗病毒作用。

Antiviral Res. 2022 Jun;202:105311. doi: 10.1016/j.antiviral.2022.105311. Epub 2022 Apr 4.

Identifying the optimal dose of ritonavir in the treatment of malignancies.确定利托那韦在恶性肿瘤治疗中的最佳剂量。

Metab Brain Dis. 2014 Jun;29(2):533-40. doi: 10.1007/s11011-013-9448-5. Epub 2013 Nov 19.

Replication-independent expression of anti-apoptosis marker genes in human peripheral blood mononuclear cells infected with the wild-type HIV-1 and reverse transcriptase variants.野生型 HIV-1 及逆转录酶变异体感染的人外周血单个核细胞中抗凋亡标记基因的复制独立性表达。

Viral Immunol. 2012 Feb;25(1):12-20. doi: 10.1089/vim.2011.0057. Epub 2012 Jan 12.

Repositioning HIV protease inhibitors as cancer therapeutics.将HIV蛋白酶抑制剂重新定位为癌症治疗药物。

Curr Opin HIV AIDS. 2008 Nov;3(6):666-75. doi: 10.1097/COH.0b013e328313915d.

Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition.人类免疫缺陷病毒蛋白酶抑制剂通过抑制钙蛋白酶对中性粒细胞功能和凋亡的直接作用。

Clin Vaccine Immunol. 2007 Nov;14(11):1515-21. doi: 10.1128/CVI.00130-07. Epub 2007 Sep 12.

Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.1型人类免疫缺陷病毒蛋白酶抑制剂可阻断Toll样受体2（TLR2）和TLR4诱导的核因子κB激活。

Antimicrob Agents Chemother. 2004 Oct;48(10):3905-11. doi: 10.1128/AAC.48.10.3905-3911.2004.

In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells.通过用灭活病毒脉冲树突状细胞扩增的自体CD8(+) T细胞在体外根除人类免疫缺陷病毒。

J Virol. 2001 Oct;75(19):8949-56. doi: 10.1128/JVI.75.19.8949-8956.2001.

Current concepts in human immunodeficiency virus infection and AIDS.人类免疫缺陷病毒感染与艾滋病的当前概念

Clin Diagn Lab Immunol. 1999 May;6(3):295-305. doi: 10.1128/CDLI.6.3.295-305.1999.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验